France: EverImmune, a biotechnology company specialised in the development of live biotherapeutic products in the field of microbiota oncology, has raised more than €5m (US$5.7m) in a Series A funding from undisclosed private investors. EverImmune is a spinoff from Gustave Roussy; Europe’s first cancer institute, based near Paris. It harnesses the gut microbiota for the…
©2023 All rights reserved LaingBuisson 
